| Company | Date | Position | Consensus ⓘ | Price Target ⓘ | 1-Yr Return |
|---|---|---|---|---|---|
|
INSM
Insmed
|
Dec 18, 2025 | BUY |
Strong Buy
+82.1% avg upside
36 analysts
|
$219.00
128.56% Upside
|
-40.9% |
|
PTCT
PTC Therapeutics
|
Oct 28, 2025 | BUY |
Buy
-1.4% avg upside
29 analysts
|
$77.00
2.44% Downside
|
+16.4% |
|
IMCR
Immunocore Holdings
|
Aug 24, 2025 | BUY |
Strong Buy
+124.5% avg upside
22 analysts
|
$48.00
67.78% Upside
|
-13.9% |
|
ZLAB
Zai Lab
|
Aug 24, 2025 | BUY |
Strong Buy
+223.0% avg upside
13 analysts
|
$52.00
186.08% Upside
|
-49.8% |
|
VRDN
Viridian Therapeutics
|
Aug 24, 2025 | BUY |
Strong Buy
+103.6% avg upside
32 analysts
|
$44.00
164.63% Upside
|
-13.3% |
|
ASND
Ascendis Pharma
|
Jul 29, 2025 | BUY |
Strong Buy
+16.9% avg upside
24 analysts
|
$235.00
1.75% Upside
|
+36.7% |
|
COGT
Cogent Biosciences
|
Jul 07, 2025 | BUY |
Strong Buy
+7.4% avg upside
26 analysts
|
$28.00
19.00% Downside
|
+266.1% |
|
KYMR
Kymera Therapeutics
|
Jun 25, 2025 | BUY |
Strong Buy
+9.0% avg upside
36 analysts
|
$64.00
29.26% Downside
|
+93.5% |
|
INCY
Incyte
|
Jun 16, 2025 | BUY |
Buy
+1.0% avg upside
47 analysts
|
$82.00
16.60% Downside
|
+40.1% |
|
SNDX
Syndax Pharmaceuticals
|
Jun 05, 2025 | BUY |
Strong Buy
+88.7% avg upside
27 analysts
|
$43.00
126.38% Upside
|
+55.4% |
|
CNTA
Centessa Pharmaceuticals
|
Jun 04, 2025 | BUY |
Buy
-14.4% avg upside
19 analysts
|
$27.00
32.51% Downside
|
+217.6% |
|
VSTM
Verastem
|
Jun 04, 2025 | BUY |
Strong Buy
+259.4% avg upside
23 analysts
|
$19.00
361.09% Upside
|
-37.4% |
|
SMMT
Summit Therapeutics
|
May 31, 2025 | BUY |
Strong Buy
+112.6% avg upside
27 analysts
|
$44.00
219.96% Upside
|
-1.0% |
|
LEGN
Legend Biotech
|
May 13, 2025 | BUY |
Strong Buy
+134.2% avg upside
27 analysts
|
$91.00
225.83% Upside
|
-7.8% |
|
JP:4502
Takeda Pharmaceutical Co
|
May 08, 2025 | BUY |
Strong Buy
+6.2% avg upside
8 analysts
|
$5100.00
3.43% Upside
|
· |
|
ALDX
Aldeyra Therapeutics
|
Apr 04, 2025 | BUY |
Strong Buy
+716.1% avg upside
21 analysts
|
$6.00
206.16% Upside
|
-12.2% |
|
OPTEY
Opthea Limited Sponsored ADR
|
Mar 25, 2025 | SELL |
Hold
+37213.4% avg upside
7 analysts
|
$1.00
4875.12% Upside
|
· |
|
SLN
Silence Therapeutics
|
Feb 27, 2025 | BUY |
Strong Buy
+372.0% avg upside
9 analysts
|
$30.00
332.83% Upside
|
+15.2% |
|
BCYC
Bicycle Therapeutics
|
Feb 25, 2025 | BUY |
Strong Buy
+504.5% avg upside
20 analysts
|
$42.00
949.99% Upside
|
-48.4% |
|
ONC
BeOne Medicines
|
Feb 21, 2025 | BUY |
Strong Buy
+28.6% avg upside
28 analysts
|
$286.00
5.91% Upside
|
+41.8% |
|
FDMT
4D Molecular Therapeutics
|
Feb 10, 2025 | BUY |
Strong Buy
+266.1% avg upside
15 analysts
|
$40.00
314.13% Upside
|
+71.2% |
|
ADCT
ADC Therapeutics
|
Jan 21, 2025 | BUY |
Buy
+450.4% avg upside
12 analysts
|
$10.00
817.36% Upside
|
+102.8% |
|
TIL
Instil Bio
|
Jan 07, 2025 | BUY |
Buy
+343.4% avg upside
8 analysts
|
$52.00
593.31% Upside
|
-69.3% |
|
RVMD
Revolution Medicines
|
Dec 20, 2024 | BUY |
Strong Buy
-12.2% avg upside
32 analysts
|
$86.00
47.22% Downside
|
+78.8% |
|
FHTX
Foghorn Therapeutics
|
Dec 16, 2024 | BUY |
Strong Buy
+187.5% avg upside
17 analysts
|
$14.00
237.38% Upside
|
-18.7% |
|
KROS
Keros Therapeutics
|
Dec 13, 2024 | BUY |
Strong Buy
+139.8% avg upside
21 analysts
|
$23.00
115.93% Upside
|
+14.2% |
|
MLTX
MoonLake Immunotherapeutics
|
Dec 11, 2024 | BUY |
Strong Buy
+51.6% avg upside
20 analysts
|
$65.00
238.40% Upside
|
-73.7% |
|
IMTX
Immatics
|
Nov 18, 2024 | BUY |
Strong Buy
+87.3% avg upside
15 analysts
|
$20.00
104.46% Upside
|
+32.0% |
|
ADAG
Adagene
|
Nov 15, 2024 | HOLD |
Strong Buy
+92.6% avg upside
8 analysts
|
$3.50
11.16% Downside
|
-15.3% |
|
AUTL
Autolus Therapeutics
|
Nov 12, 2024 | BUY |
Strong Buy
+605.8% avg upside
16 analysts
|
$13.00
760.99% Upside
|
-59.2% |
|
IBRX
ImmunityBio
|
Aug 18, 2024 | BUY |
Strong Buy
+55.2% avg upside
12 analysts
|
$8.00
8.63% Upside
|
-39.2% |
|
AVBP
ArriVent BioPharma, Inc.
|
Aug 15, 2024 | BUY |
Strong Buy
+37.1% avg upside
15 analysts
|
$35.00
10.34% Upside
|
-18.1% |
|
ARTV
Artiva Biotherapeutics, Inc.
|
Aug 13, 2024 | BUY |
Strong Buy
+239.4% avg upside
7 analysts
|
$21.00
113.77% Upside
|
-76.2% |
|
AGEN
Agenus
|
Jul 19, 2024 | HOLD |
Strong Buy
+165.3% avg upside
17 analysts
|
$7.00
133.37% Upside
|
+2.7% |
|
PROK
ProKidney
|
Jun 10, 2024 | BUY |
Buy
+261.9% avg upside
12 analysts
|
$6.00
227.86% Upside
|
-66.9% |
|
HK:9966
Alphamab Oncology
|
Jun 10, 2024 | BUY |
Strong Buy
-4.3% avg upside
1 analyst
|
$7.00
4.32% Downside
|
· |
|
CCCC
C4 Therapeutics
|
Mar 04, 2024 | BUY |
Strong Buy
+341.8% avg upside
19 analysts
|
$14.00
237.32% Upside
|
-77.7% |
|
NBP
NovaBridge Biosciences
|
Feb 09, 2024 | BUY |
Strong Buy
+1306.0% avg upside
14 analysts
|
$5.00
233.33% Upside
|
· |
|
CABA
Cabaletta Bio
|
Feb 04, 2024 | BUY |
Strong Buy
+390.0% avg upside
16 analysts
|
$36.00
1167.63% Upside
|
-89.7% |
|
ACET
Adicet Bio
|
Jan 05, 2024 | BUY |
Strong Buy
+212.8% avg upside
14 analysts
|
$8.00
1.16% Downside
|
-59.0% |
|
CLLS
Cellectis SA
|
Dec 14, 2022 | BUY |
Strong Buy
+569.9% avg upside
16 analysts
|
$14.00
369.87% Upside
|
+39.1% |
|
CNTB
Connect Biopharma Holdings
|
Oct 05, 2022 | BUY |
Strong Buy
+226.3% avg upside
11 analysts
|
$7.00
250.09% Upside
|
-13.0% |
|
GLUE
Monte Rosa Therapeutics
|
Aug 15, 2022 | BUY |
Strong Buy
+27.3% avg upside
14 analysts
|
$20.00
9.29% Upside
|
-33.8% |
|
HRTX
Heron Therapeutics
|
Jan 18, 2022 | BUY |
Strong Buy
+6439.5% avg upside
21 analysts
|
$23.00
5408.97% Upside
|
-61.6% |
|
BCAB
BioAtla
|
Jan 17, 2022 | BUY |
Strong Buy
+2580.2% avg upside
13 analysts
|
$68.00
1760.45% Upside
|
-69.6% |
|
HCM
HUTCHMED
|
Aug 03, 2021 | BUY |
Strong Buy
+208.7% avg upside
9 analysts
|
$52.00
405.78% Upside
|
-71.2% |
|
ALLO
Allogene Therapeutics
|
May 20, 2021 | BUY |
Strong Buy
+662.8% avg upside
28 analysts
|
$53.00
2550.08% Upside
|
-72.1% |
|
IMA
ImageneBio
|
Apr 20, 2021 | BUY |
Strong Buy
+179.6% avg upside
12 analysts
|
$27.00
349.99% Upside
|
-66.2% |
|
ZNTL
Zentalis Pharmaceuticals
|
Apr 13, 2021 | BUY |
Buy
+295.1% avg upside
16 analysts
|
$63.00
1602.76% Upside
|
-40.9% |
Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.